Immunovant, Inc. (NASDAQ:IMVT) Shares Purchased by EntryPoint Capital LLC

EntryPoint Capital LLC increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT) by 288.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,912 shares of the company’s stock after acquiring an additional 2,163 shares during the period. EntryPoint Capital LLC’s holdings in Immunovant were worth $94,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Immunovant by 14.0% during the third quarter. Vanguard Group Inc. now owns 6,233,146 shares of the company’s stock worth $239,290,000 after purchasing an additional 764,530 shares in the last quarter. CoreCap Advisors LLC boosted its position in Immunovant by 11.2% during the fourth quarter. CoreCap Advisors LLC now owns 6,407 shares of the company’s stock worth $270,000 after purchasing an additional 647 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in Immunovant during the fourth quarter worth $5,109,000. China Universal Asset Management Co. Ltd. boosted its position in Immunovant by 398.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,734 shares of the company’s stock worth $705,000 after purchasing an additional 13,374 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its position in Immunovant by 590.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 42,865 shares of the company’s stock worth $1,806,000 after purchasing an additional 36,659 shares in the last quarter. Institutional investors and hedge funds own 47.08% of the company’s stock.

Insider Transactions at Immunovant

In other news, CEO Peter Salzmann sold 16,163 shares of the business’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $29.65, for a total value of $479,232.95. Following the sale, the chief executive officer now owns 1,036,716 shares of the company’s stock, valued at approximately $30,738,629.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Peter Salzmann sold 16,163 shares of the business’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $29.65, for a total transaction of $479,232.95. Following the sale, the chief executive officer now directly owns 1,036,716 shares of the company’s stock, valued at $30,738,629.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Eva Renee Barnett sold 3,123 shares of the business’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $29.69, for a total value of $92,721.87. Following the sale, the chief financial officer now directly owns 347,544 shares in the company, valued at $10,318,581.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 48,658 shares of company stock valued at $1,425,962. Corporate insiders own 5.90% of the company’s stock.

Immunovant Stock Up 2.4 %

Immunovant stock traded up $0.67 during mid-day trading on Friday, hitting $28.47. 319,620 shares of the company’s stock traded hands, compared to its average volume of 1,194,323. The firm has a 50 day moving average price of $27.62 and a 200 day moving average price of $31.69. The company has a market cap of $4.16 billion, a PE ratio of -14.93 and a beta of 0.67. Immunovant, Inc. has a one year low of $18.82 and a one year high of $45.58.

Immunovant (NASDAQ:IMVT) last announced its earnings results on Wednesday, May 29th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.08). During the same quarter in the previous year, the company earned ($0.46) earnings per share. On average, analysts expect that Immunovant, Inc. will post -2.11 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on IMVT. Cantor Fitzgerald restated an “overweight” rating on shares of Immunovant in a research report on Tuesday, June 18th. HC Wainwright restated a “buy” rating and issued a $51.00 price objective on shares of Immunovant in a research report on Thursday, May 30th. Finally, Oppenheimer reduced their price objective on Immunovant from $50.00 to $46.00 and set an “outperform” rating on the stock in a research report on Monday, June 3rd. Fifteen analysts have rated the stock with a buy rating, According to data from MarketBeat, Immunovant has a consensus rating of “Buy” and an average price target of $49.73.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.